trial

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

NCTId NCT02901587
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 119 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2018-04-18
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
119 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-09
Primary completion
2018-04-18
Eligibility
ALL · 21 Years · 60 Years

Interventions & indications

Drugs
Lu AF35700 (30 mg/day)Lu AF35700 (10 mg/day)Quetiapine

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

1 total
Long Beach, United States

Facts & assertions

4 sourced
Enrollment
119
Phase
PHASE1
Primary Completion Date
2018-04-18
Status
COMPLETED
relationships
The graph out of here
drug
Lu AF35700 (30 mg/day)
drug
Lu AF35700 (10 mg/day)
drug
Quetiapine
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication